Drug application
IMITREX (SUMATRIPTAN SUCCINATE)
Drugs@FDA NDA 020080 · GLAXOSMITHKLINE
Key facts
| Drug name | IMITREX |
|---|---|
| Active ingredients | SUMATRIPTAN SUCCINATE |
| Application type | NDA |
| Application number | 020080 |
| Company | GLAXOSMITHKLINE |
| Dosage forms | SOLUTION, SUBCUTANEOUS |
| Strength | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** |
| Marketing status | Discontinued |
| TE codes | AP |
| Reference listed drug | Yes |
| Latest submission class | Type 1 - New Molecular Entity |
| Latest submission status date | Dec 28, 1992 |
At a glance
- 1–9 Submissions
- 10–99 Supplements
- 10–99 Label versions
- 1–9 Products
- 1–9 Therapeutic equivalents
- No FDA letters on file
- No FDA reviews on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: